REDUCED ABILITY TO CLEAR ULTRAFILTERABLE PLATINUM WITH REPEATED COURSES OF CISPLATIN

被引：54

作者：

REECE, PA

STAFFORD, I

RUSSELL, J

GILL, PG

机构：

[1] ROYAL ADELAIDE HOSP,ONCOL UNIT,ADELAIDE,SA 5000,AUSTRALIA

[2] UNIV ADELAIDE,ROYAL ADELAIDE HOSP,ADELAIDE,SA 5001,AUSTRALIA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1986年 / 4卷 / 09期

关键词：

D O I：

10.1200/JCO.1986.4.9.1392

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1392 / 1398

页数：7

共 40 条

[1] A HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY WITH IMPROVED SELECTIVITY FOR CISPLATIN AND ACTIVE PLATINUM(II) COMPLEXES IN PLASMA ULTRAFILTRATE [J].

ANDREWS, PA ;

WUNG, WE ;

HOWELL, SB .

ANALYTICAL BIOCHEMISTRY, 1984, 143 (01) :46-56

[2] URINE ANALYSIS OF PLATINUM SPECIES DERIVED FROM CIS-DICHLORODIAMMINEPLATINUM(II) BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY FOLLOWING DERIVATIZATION WITH SODIUM DIETHYLDITHIOCARBAMATE [J].

BANNISTER, SJ ;

STERNSON, LA ;

REPTA, AJ .

JOURNAL OF CHROMATOGRAPHY, 1979, 173 (02) :333-342

[3]

BENNETT WM, 1980, CANCER TREAT REP, V64, P921

[4]

BIRD JE, 1984, J PHARMACOL EXP THER, V231, P752

[5]

BUAMAH PK, 1982, CANCER CHEMOTH PHARM, V8, P281

[6]

CAMPBELL AB, 1983, CANCER TREAT REP, V67, P169

[7]

CATERSON R, 1983, RES COMMUN CHEM PATH, V41, P255

[8] CLINICAL-PHARMACOLOGY OF HIGH-DOSE CISPLATIN [J].

CORDEN, BJ ;

FINE, RL ;

OZOLS, RF ;

COLLINS, JM .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1985, 14 (01) :38-41

[9] THE EFFECT OF PRIOR CISPLATIN THERAPY ON THE PHARMACOKINETICS OF HIGH-DOSE METHOTREXATE [J].

CROM, WR ;

PRATT, CB ;

GREEN, AA ;

CHAMPION, JE ;

CROM, DB ;

STEWART, CF ;

EVANS, WE .

JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (06) :655-661

[10] THE MECHANISM OF RENAL CLEARANCE OF CISPLATIN (CIS-DICHLORODIAMMINE PLATINUM-II) AND ITS MODIFICATION BY FUROSEMIDE AND PROBENECID [J].

DALEYYATES, PT ;

MCBRIEN, DCH .

BIOCHEMICAL PHARMACOLOGY, 1982, 31 (13) :2243-2246

← 1 2 3 4 →